Recursion Pharmaceuticals, Inc. (RXRX)
After hours:
- Zacks
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.
- Zacks
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- GlobeNewswire
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
Company to host public L(earnings) Call on May 9 at 5:00 pm ETSALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern
